PURE Bioscience (PURE) details fiscal Q1 2025 financial results update

Rhea-AI Filing Summary

PURE Bioscience, Inc. filed a current report to notify investors that it has issued a press release announcing financial results for its fiscal first quarter ended October 31, 2025. The press release, dated December 15, 2025, is included as Exhibit 99.1 and contains details about the company’s operations and financial condition for that period.

The company explains that this information is being furnished rather than filed, so it is not subject to certain liability provisions under the Securities Exchange Act and is not automatically incorporated into other SEC documents.

false 0001006028 0001006028 2025-12-15 2025-12-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 15, 2025

PURE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-14468		33-0530289
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

771 Jamacha Rd., #512 El Cajon, California		92019
(Address of principal executive offices)		(Zip Code)

9669 Hermosa Avenue Rancho Cucamonga, California		91730
(Address of principal executive offices)		(Zip Code)

(Former name or former address, if changed since last report)

Registrant’s telephone number, including area code: (619) 596-8600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On December 15, 2025, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal first quarter ended October 31, 2025 and related information. A copy of the press release is attached as Exhibit 99.1.

The information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

	99.1	Press Release, dated December 15, 2025.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PURE BIOSCIENCE, INC.
Dated: December 15, 2025	By:	/s/ Robert F. Bartlett
		Robert F. Bartlett
		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release, dated December 15, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

FAQ

What did PURE (PURE) disclose in this SEC filing?

PURE Bioscience, Inc. disclosed that it issued a press release announcing its financial results and related information for the fiscal first quarter ended October 31, 2025, and attached that release as Exhibit 99.1.

Which period do PURE Bioscience's latest reported results cover?

The filing states that the press release contains financial results for PURE Bioscience’s fiscal first quarter ended October 31, 2025.

How did PURE Bioscience release its fiscal first-quarter 2025 results?

PURE Bioscience released its fiscal first-quarter 2025 results through a press release dated December 15, 2025, which is referenced in the filing and attached as Exhibit 99.1.

What is Exhibit 99.1 in PURE Bioscience's current report?

Exhibit 99.1 is the press release dated December 15, 2025, in which PURE Bioscience announces its financial results for the fiscal first quarter ended October 31, 2025.

Is the financial information in this PURE Bioscience filing considered filed or furnished?

The company states that the information under Item 2.02 is being furnished and not deemed filed, meaning it is not subject to Section 18 liabilities and is not incorporated by reference into other SEC documents.

Who signed the current report for PURE Bioscience?

The report was signed on behalf of PURE Bioscience, Inc. by Robert F. Bartlett, the company’s Chief Executive Officer.